Corporate news

Grifols invests in the project led by AlbaJuna Therapeutics, a spin-off from IrsiCaixa, to fund the development of therapeutic antibodies against HIV AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the "natural killer" cells responsible for destroying cells infected by the virus
+ info

Grifols Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine in U.S. Almost all cases of tetanus in the U.S. occur in people who have never been immunized or who have not had a tetanus booster shot within the preceding 10 years
+ info

Grifols makes public its succession plan: the envisaged generational handover reiterates the commitment of the founding family to the company From 1 January 2017 Victor Grifols Roura will be succeeded by his brother, Raimon Grifols, and his son, Víctor Grifols Deu, who will become joint and several chief executive officers of the company. Víctor Grifols will continue holding his position as non-executive chairman of the board of directors
+ info

Highlights

Manufacturing

Manufacturing
We are a solid company with an international dimension.

Corporate Commitment

People
We contribute to improving people's health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.

When a Dream Comes True. An Illustrated History of 75 Years of Grifols

Read When a Dream Comes True: An illustrated history of 75 years of Grifols to discover the company's roots, and learn more about our history and the development of the company.  + info

 

get to know us better